- Home
- NAII vs MBRX Comparison
NAII vs MBRX Comparison
Compare NAII & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAII
- MBRX
- Stock Information
- Founded
- NAII 1980
- MBRX 2015
- Country
- NAII United States
- MBRX United States
- Employees
- NAII N/A
- MBRX N/A
- Industry
- NAII Medicinal Chemicals and Botanical Products
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- NAII Health Care
- MBRX Health Care
- Exchange
- NAII Nasdaq
- MBRX Nasdaq
- Market Cap
- NAII 21.2M
- MBRX 23.5M
- IPO Year
- NAII 1987
- MBRX 2016
- Fundamental
- Price
- NAII $2.70
- MBRX $0.48
- Analyst Decision
- NAII
- MBRX Strong Buy
- Analyst Count
- NAII 0
- MBRX 4
- Target Price
- NAII N/A
- MBRX $5.00
- AVG Volume (30 Days)
- NAII 21.8K
- MBRX 2.4M
- Earning Date
- NAII 11-12-2025
- MBRX 11-12-2025
- Dividend Yield
- NAII N/A
- MBRX N/A
- EPS Growth
- NAII N/A
- MBRX N/A
- EPS
- NAII N/A
- MBRX N/A
- Revenue
- NAII $129,860,000.00
- MBRX N/A
- Revenue This Year
- NAII N/A
- MBRX N/A
- Revenue Next Year
- NAII N/A
- MBRX N/A
- P/E Ratio
- NAII N/A
- MBRX N/A
- Revenue Growth
- NAII 14.12
- MBRX N/A
- 52 Week Low
- NAII $2.57
- MBRX $0.25
- 52 Week High
- NAII $4.95
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- NAII 42.60
- MBRX 51.13
- Support Level
- NAII $2.59
- MBRX $0.44
- Resistance Level
- NAII $2.88
- MBRX $0.52
- Average True Range (ATR)
- NAII 0.16
- MBRX 0.04
- MACD
- NAII 0.02
- MBRX -0.00
- Stochastic Oscillator
- NAII 22.45
- MBRX 52.16
About NAII Natural Alternatives International Inc.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.